Clinical Trial Update: An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Open-label Phase 2 study of tomivosertib (eFT508) in advanced castration-resistant prostate cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Tomivosertib (eFT508) (tomivosertib)

Snippet

Sponsor: Effector Therapeutics | Conditions: Castrate-resistant Prostate Cancer (CRPC) | Phase 2 | Status: TERMINATED | Results posted: 2024-06-21